T
Thorsten Holzkaemper
Researcher at Eli Lilly and Company
Publications - 14
Citations - 107
Thorsten Holzkaemper is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications receiving 66 citations.
Papers
More filters
Journal ArticleDOI
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
Bruno Fautrel,Rieke Alten,Bruce Kirkham,Inmaculada de la Torre,Frederick Durand,Jane Barry,Thorsten Holzkaemper,Walid D. Fakhouri,Peter C. Taylor +8 more
TL;DR: The timely and effective use of patient-reported outcomes (PROs) could encourage physicians to focus more on the impact of RA on patients and how patients are feeling, ultimately leading to a more patient-centered approach and improved patient care.
Journal ArticleDOI
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.
Kristian Reich,Curdin Conrad,Lars Erik Kristensen,Saxon D Smith,Luis Puig,Phoebe Rich,Christophe Sapin,Thorsten Holzkaemper,Uffe Koppelhus,Christopher Schuster,Christopher Schuster +10 more
TL;DR: In this paper, complete resolution of NP at week 24 and 26 is an unambiguous nail outcome accessible for indirect treatment comparison for indirect comparison of indirect treatment compared with direct treatment comparison.
Journal ArticleDOI
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
Rieke Alten,Gerd R Burmester,Marco Matucci-Cerinic,Jean-Hugues Salmon,Pedro López-Romero,Walid D. Fakhouri,Inmaculada de la Torre,Liliana Zaremba-Pechmann,Thorsten Holzkaemper,Bruno Fautrel +9 more
TL;DR: RA-BE-REAL as discussed by the authors is an ongoing, prospective, observational, 36-month study in patients with rheumatoid arthritis starting baricitinib or any other targeted synthetic (ts) or any biologic (b) disease-modifying antirheumatic drug (DMARD) for the first time, and the primary objective of estimating time until discontinuation from any cause (excluding sustained response) of the initial treatment.
Journal ArticleDOI
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
Charles Lynde,Elisabeth Riedl,Julia-Tatjana Maul,Tiago Torres,Andreas Pinter,Gabriella Fabbrocini,Flavia Daniele,Alan J. M. Brnabic,Catherine Reed,S Wilhelm,Thorsten Holzkaemper,Christopher John Schuster,Lluís Puig +12 more
TL;DR: In this article , the authors provided direct comparative effectiveness data at week 12 between anti-interleukin (IL)-17A biologics relative to other approved biologic drugs for the treatment of plaque psoriasis across seven clinically relevant patient subgroups in the real-world setting.